A Clinical Study of CHT102 in MSLN-Positive Advanced Pancreatic Cancer — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

A Clinical Study of CHT102 in MSLN-Positive Advanced Pancreatic Cancer — Stella

Home/Advanced Pancreatic Cancers/

View on ClinicalTrials.gov

Recruiting

Back to Advanced Pancreatic Cancers trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

China

Tianjin Medical University Cancer Institute & Hospital, Tianjin

Key details

Phase

Early testing

Sponsor

Tianjin Medical University Cancer Institute and Hospital

Collaborators

Nanjing Calmhome Cell and Gene Engineering Institute Co., Ltd.

Enrollment target

~21 participants

Started

December 2024

Primary completion

December 2027

Age range

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

18 Years – 70 Years

Last updated April 2025